Effect of preoperative β-blockade on perioperative mortality in coronary surgery

British Journal of Anaesthesia

Volumn 90, Issue 1, 2003, Pages 27-31

  ten Broecke, P W C ^a   De Hert, S G ^a   Mertens, E ^a   Adriaensen, H F ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Complications, mortality; Risk, assessment; Surgery, cardiovascular; Sympathetic nervous system, blockade

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; OXYGEN;

ADULT; AGED; AGING; ANAMNESIS; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PEROPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SEX; SURGICAL MORTALITY; SURVIVAL RATE;

EID: 0037236122     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeg013     Document Type: Article

References (38)

1. Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting: the Society of Thoracic Surgeons national database experience. Ann Thorac Surg 1994; 57: 12-19
2. Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation 1989; 79 (Suppl 1): 3-12
3. Higgins TL, Estafanous FG, Loop FD, et al. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients: a clinical severity score. JAMA 1992; 267: 2344-8
4. Higgins TL. Quantifying and assessing outcome in cardiac surgery. J Cardiothorac Vasc Anesth 1998; 12: 330-40
5. Tu JV, Haglal SB, Naylor CD. Multicenter validation of a risk index for mortality, intensive care unit stay, and overall hospital length of stay after cardiac surgery. Circulation 1995; 91: 677-84
6. Roques F, Nashef SAM, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15: 816-23
7. O'Connor GT, Plume SK, Olmstead EM, et al. for the Northern New England Cardiovascular Disease Study Group. Multivariate prediction of in-hospital mortality associated with coronary artery bypass graft surgery. Circulation 1992; 85: 2110-18
8. Sprung J, Abdelmalak B, Gottlieb A, et al. Analysis of risk factors for myocardial infarction and cardiac mortality after major vascular surgery. Anesthesiology 2000; 93: 129-40
9. Arbous MS, Grobbee DE, van Kleef JW, Meursing AEE. Dutch case-control study of anaesthesia-related morbidity and mortality. Anaesthesia 1998; 53: 162-8
10. Ivanov J, Tu JV, Naylor CD. Ready-made, recalibrated, or remodeled? Issues in the use of risk indexes for assessing mortality after coronary artery bypass graft surgery. Circulation 1999; 99: 2098-104
11. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5
12. Kostis JB, Clifton RL, Cosgrove NM, Wilson AC. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Am Heart J 1997; 133: 550-7
13. Fuberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary artery disease. Circulation 1995; 92: 1326-31
14. Weightman WM, Gibbs NM, Sheminant MR, et al. Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and β-adrenergic blockers predict survival. Anesth Analg 1999; 88: 286-91
15. Ferguson TB, Coombs LP, Peterson ED. Preoperative β-blocker use and mortality and morbidity following CABG surgery in North America. JAMA 2002; 287: 2221-7
16. Zaugg M, Tagliente T, Lucchinetti E, et al. Beneficial effects from β-adrenergic blockade in elderly patients undergoing noncardiac surgery. Anesthesiology 1999; 91: 1674-86
17. Warltier DC. β-adrenergic-blocking drugs, incredibly useful, incredibly underutilized. Anesthesiology 1998; 88: 2-5
18. Mangano D, Layug E, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 1996; 335: 1713-20
19. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341: 1789-94
20. Boersma E, Poldermans D, Bax JJ, et al. for the Decrease Study Group. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 2001; 285: 1865-73
21. Poldermans D, Boersma E, Bax JJ, et al. for the Decrease Study Group. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J 2001; 22: 1353-8
22. Akhtar S, Barash PG. Significance of beta-blockers in the perioperative period. Current Opin Anaesthesiol 2002; 15: 27-35
23. O'Hara DA, Duff AMSE, Berlin JA, et al. The effect of anesthetic technique on postoperative outcomes in hip fracture repair. Anesthesiology 2000; 92: 947-57
24. Kaplan JA, Dunbar RW, Bland JW, Sumpter R, Jones EL. Propranolol and cardiac surgery: a problem for the anesthesiologist? Anesth Analg 1975; 54: 571-8
25. Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior β-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention. Circulation 2000; 102: 166-72
26. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997; 18: 560-5
27. CIBIS II Investigators and committees. The cardiac insufficiency bisoprolol study. II. (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13
28. Olsson G, Wikstrand J, Warnold I. Metoprolol induced reduction in postinfarct mortality: pooled results from five double blind randomised trials. Eur Heart J 1992; 13: 28-32
29. Olsson G, Tuomileho J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients: mortality results from the MAPHY study. Am J Hypertens 1991; 4: 151-8
30. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. New Engl J Med 1998; 339: 489-97
31. Yeager RA, Moneta GL, Edwards JM, Taylor LM Jr, McConnell DB, Porter JM. Reducing perioperative myocardial infarction following vascular surgery. Arch Surg 1995; 130: 869-73
32. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. Anesthesiology 1998; 88: 7-17
33. Piriou V, Aouifi A, Lehot JJ. Intérêt des bêta-bloquants en médecine périopératoire. Can J Anaesth 2000; 47: 653-72
34. Guvendik L, Davies M, Parker DJ. Oral beta-blockade with hypothermic potassium cardioplegia in cardiac surgery: Is there an additive effect? Thorac Cardiovasc Surg 1986; 34: 25-9
35. Bühler FR, Bolli P. The concept of beta-adrenoreceptor blockade in the primary and secondary prevention of cardiac mortality and morbidity. Triangle 1980; 19: 35-45
36. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol XL/XL Randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-7
37. Ogunyankin KO, Singh BN. Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone. Am J Cardiol 1999; 84: 76R-82R
38. de Graeff PA. β-blokkers bij hartfalen. Geneesmiddelenbulletin 2000; 34: 65-70